The Clinical and Symptomatic Burden Among Older Adults with Respiratory Syncytial Virus: A Real-World Survey in Five European Countries Authors: Diana Mendes, James Lucas, Emily Quinones, Mayesha Chowdhury, Libby Turner, Stéphane Fiévez, Caroline Lade, Roberto Di Virgilio, Alejandra López-Ibáñez de Aldecoa, James Piercy, Reiko Sato Published: 2026 ABSTRACT IntroductionAlthough respiratory syncytial virus (RSV) is a common cause of respiratory illness in older adults (≥ 60 years), data on overall burden remain limited. This study investigated the clinical and symptomatic burden in older adults with RSV in Europe.MethodsData were drawn from the Adelphi RSV Disease Specific Programme (DSP)™, a cross-sectional survey of physicians and their patients with RSV, conducted across Europe between Q4 2023–Q2 2024. Physicians reported demographics, clinical characteristics, symptoms, disease progression, comorbidities, and impact on health-related quality of life (HRQoL) and activities of daily living (ADL). Patients self-reported HRQoL via the Respiratory Infection Intensity and Impact Questionnaire (RiiQ™) and EQ-5D-5L. Patients were grouped as: A-RSV (Acute, symptom onset 0-< 4 weeks), O-RSV (Ongoing, symptom onset 4-< 12 weeks), P-RSV (Post-acute, symptom onset 12-≤ 52 weeks) and H-RSV (Post-hospital discharge, symptom onset ≤ 52 weeks).ResultsOverall, 602 physicians reported data on 1581 patients (n = 237 A-RSV, n = 196 O-RSV, n = 588 P-RSV, n = 560 H-RSV). Of those with H-RSV, 34.1% were aged 75 + (A-RSV: 20.7%) and 58.7% had 3 + concomitant conditions (A-RSV: 29.2%) at diagnosis. RSV affected patients’ HRQoL and ADL, psychological well-being, relationships and ability to support/care for family members, with differences observed across groups, particularly in patients with H-RSV (all p < 0.01). Of the 417 (26.4%) patients who self-reported HRQoL, differences across RiiQ™ symptom scores were observed (all p < 0.05), indicating higher burden in the A-RSV and H-RSV groups. Differences in overall EQ-5D-5L scores and in the EQ-5D mobility, self-care and anxiety/depression domains were also significant (all p < 0.05).ConclusionsRSV was associated with high burden. Patients experienced a high symptom burden, and patients with O-RSV, P-RSV and H-RSV experienced persistent symptoms over a long duration post-infection. Patients reported poor HRQoL across all outcome measures. Given this burden, focus on preventive measures such as RSV vaccination should be prioritized.Supplementary InformationThe online version contains supplementary material available at 10.1007/s40121-026-01380-x. Key Summary Points Why carry out this study? Although respiratory syncytial virus (RSV) is a common cause of acute respiratory illness, real-world data on humanistic burden in older adults (≥ 60 years) remain limited.This study investigated the clinical and humanistic burden in older adults with RSV in Europe. What was learned from the study? RSV was associated with high clinical burden, with many patients experiencing persistent high symptom burden over a long period of time.Burden was particularly high depending on severity and symptom duration groups, with patients reporting low health-related quality of life (HRQoL) across all reported measures.Given the high humanistic burden, focus on preventive measures such as RSV vaccination should be prioritized. Why carry out this study? Although respiratory syncytial virus (RSV) is a common cause of acute respiratory illness, real-world data on humanistic burden in older adults (≥ 60 years) remain limited.This study investigated the clinical and humanistic burden in older adults with RSV in Europe. What was learned from the study? RSV was associated with high clinical burden, with many patients experiencing persistent high symptom burden over a long period of time.Burden was particularly high depending on severity and symptom duration groups, with patients reporting low health-related quality of life (HRQoL) across all reported measures.Given the high humanistic burden, focus on preventive measures such as RSV vaccination should be prioritized. Introduction Respiratory syncytial virus (RSV), characterized by symptoms including nasal congestion, fever, cough and fatigue, is a common cause of acute respiratory illness [1]. Although well studied in children, the impact of RSV in adults is becoming increasingly recognized, particularly in adults aged ≥ 60 years and those with existing comorbidities or underlying health conditions [2]. It is estimated that RSV is responsible for 5.1% of respiratory infections in older adults in Europe annually, reaching 6.7% during seasonal peaks, with a case fatality rate of 8.2% of medically attended cases [3]. Although generally mild, RSV can result in severe lower respiratory tract symptoms including shortness of breath and wheezing. This may lead to more serious complications such as bronchitis and pneumonia, particularly in older adults and those at risk of severe RSV infections [1, 3]. While age itself is a risk factor for severe RSV, other risk factors include underlying medical conditions such as chronic cardiac disease, chronic respiratory disease, diabetes mellitus, chronic liver disease, chronic kidney disease, immunosuppression and neurological disorders [4, 5]. Age and comorbid risk factors are likely linked as multimorbidity becomes increasingly prevalent with age [6]. Complications of RSV are known to have long-lasting effects on the cardiovascular and pulmonary systems [7–11]. Despite increasing awareness of the impact of RSV in older adults, data on the humanistic burden associated with RSV infection are limited, especially in those with additional comorbidities or underlying health conditions, those with more severe symptomatic presentation or those who have required hospitalizations. Existing studies on RSV focus primarily on healthcare resource use or diagnostic testing, and those that do focus on health-related quality of life (HRQoL) are either small single-centre studies or do not look at differences between patients based on severity status [12–15]. Accordingly, the objective of this study was to assess RSV-associated HRQoL in relation to the symptomatic burden of RSV in older adults in Europe, specifically severity status and symptom duration, age, and the presence or absence of additional risk factors. Methods Study Design This study was an analysis of secondary data derived from the Adelphi Real World RSV Disease Specific Programme (DSP)™, a large cross-sectional survey of physicians and their consulting patients with RSV presenting in a real-world clinical setting, with elements of retrospective data collection. The survey was conducted in Europe (France, Germany, Italy, Spain and the UK) between Q4 2023–Q2 2024. The DSP methodology has been previously described [16, 17], validated [18] and demonstrated to be representative and consistent over time [19]. The methodology is well established, with studies implemented globally across many different disease areas [17]. Physicians were recruited to participate by local fieldwork agents after completing a short screening questionnaire regarding their general workload, experience and practice setting. Physicians were non-hospital-based primary care physicians (PCPs, including general practitioners), internists or geriatricians, or hospital-based pulmonologists or infectious disease specialists. Physicians were eligible if they were personally responsible for the management of patients with RSV. Physicians were reimbursed for their participation according to fair market research rates. Patients were eligible for inclusion in the survey if they were aged 60 +, had a confirmed diagnosis of RSV via laboratory-based molecular testing (reverse transcriptase-polymerase chain reaction or rapid antigen testing), had been experiencing symptoms at the time of the survey but for < 1 year and had a known symptom onset date. Patients also could not have resided in a long-term care facility, could not be involved in a clinical trial and must have visited the physician in person for consultation. Patients were not compensated for participation. Physician-Reported Data To mitigate against selection bias, physicians completed patient record forms for their next four consecutively consulting patients with a confirmed diagnosis of RSV who visited them for routine care to establish a sample representative of patients with RSV presenting in a real-world clinical setting. The methodology set out to capture a sufficient number of acute, persistent and hospitalized patients so that enough patients were available across patient disease severity and duration groups for the purpose of analysis. However, within each group, the methodology required consecutively consulting patients to be included. Patient record forms collected cross-sectional data from the point of consultation, as well as retrospective information derived from the patient’s medical history. No follow-up data were collected. The patient record form contained detailed questions on clinical and demographic characteristics at the point of consultation, including disease severity and symptomatic burden in relation to RSV. The presence of any concomitant conditions or comorbidities diagnosed after RSV infection were collected to understand onset of complications arising from RSV. The physician’s perspective on the most bothersome symptoms and the impact of RSV on patients’ HRQoL and activities of daily living were also collected. Eight impact domains were assessed (overall quality of life, activities of daily living, psychological wellbeing, relationships, support/care for family members and severity of physical fatigue, mental fatigue and pain) at the point of data collection, scored on a 4-point scale from “no impact” to “high impact”. Additionally, retrospective data were abstracted from patient medical history, including disease history and severity, RSV diagnostic journey and symptomatic burden in relation to RSV at diagnosis. The presence of concomitant conditions or comorbidities experienced or at the point of diagnosis were documented using a pre-defined list to determine whether patients had any pre-existing risk factors for severe RSV at the time of infection. Completion of the patient record forms was undertaken by extracting data from existing patients' medical histories, as well as the judgement of the respondent physician, reflecting the evidence available when making any clinical management decisions at that consultation. Patient-Reported Data Patients were invited to complete a voluntary patient-reported questionnaire independently, without assistance from their physician. Questionnaires were returned in sealed envelopes to fieldwork partners, ensuring confidentiality of the patients’ responses. The patient-reported questionnaire included questions on the impact of RSV on their everyday lives, as well as a number of validated patient-reported outcome measures. The Respiratory Infection Intensity and Impact Questionnaire (RiiQ)™ was used to evaluate the impact and severity using the Respiratory Symptoms Scale (n = 6 items) and Systemic Symptoms Scale (n = 7 items) over the past 24 h from the patient perspective. The scales are scored by adding the score for each item (e.g., none = 0, severe = 3) in each scale and dividing by the number of items in the scale, with higher scores indicating greater severity. The RiiQ™ can be used in both research and clinical settings to gain insights into the symptom and humanistic burden posed by RSV, thereby improving treatment and outcomes [20]. The RiiQ™ was used under license as provided by Measured Solutions for Health Pty Ltd. The EQ-5D-5L index comprises five dimensions that assesses health-related quality of life (HRQoL) in terms of mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Results were expressed as an overall health state index score ranging from 0 (indicating death) to 1 (indicating full health). In addition, the EuroQol visual analogue scale (EQ-VAS) ranked overall health state, ranging between 0 (worst imaginable health) and 100 (best imaginable health) [21, 22]. Ethical Considerations Patients provided informed consent to take part in the survey and for use of their anonymized and aggregated data for research and publication in scientific journals. No identifiable protected health information was collected; all data were anonymized and aggregated prior to analysis. Data collection was undertaken in accordance with European Pharmaceutical Marketing Research Association guidelines and, as such, did not require ethics committee approval [23]. The survey materials were submitted to the PEARL Institutional Review Board (IRB study no. 2023-0459). Following a review, a waiver was granted, deeming the survey to be exempt from ethical approval. In addition, each survey was performed in full accordance with relevant legislation at the time of data collection, including the US Health Insurance Portability and Accountability Act 1996 [24] and the Declaration of Helsinki [25]. Data Analysis The cross-sectional design captured data from patients in different stages of RSV infection and recovery who were attending care at the time of survey. To understand and characterise the impact of RSV on the HRQoL of patients by symptom duration and severity (need for hospitalization), patients were stratified according to their stage of RSV infection or recovery at the time of the survey. The following four groups were analysed, and O-RSV was a further split from A-RSV:A-RSV: Acute RSV symptoms, consulting in primary care, 0–< 4 weeks since symptom onsetO-RSV: Ongoing RSV symptoms, consulting in primary care, 4–< 12 weeks since symptom onsetP-RSV: Post-acute RSV symptoms, consulting in primary care, 12–≤ 52 weeks since symptom onsetH-RSV: Post-hospital discharge for most recent RSV infection, consulting in primary or secondary care, ≤ 52 weeks since symptom onset A-RSV: Acute RSV symptoms, consulting in primary care, 0–< 4 weeks since symptom onset A-RSV: Acute RSV symptoms, consulting in primary care, 0–< 4 weeks since symptom onset O-RSV: Ongoing RSV symptoms, consulting in primary care, 4–< 12 weeks since symptom onset O-RSV: Ongoing RSV symptoms, consulting in primary care, 4–< 12 weeks since symptom onset P-RSV: Post-acute RSV symptoms, consulting in primary care, 12–≤ 52 weeks since symptom onset P-RSV: Post-acute RSV symptoms, consulting in primary care, 12–≤ 52 weeks since symptom onset H-RSV: Post-hospital discharge for most recent RSV infection, consulting in primary or secondary care, ≤ 52 weeks since symptom onset H-RSV: Post-hospital discharge for most recent RSV infection, consulting in primary or secondary care, ≤ 52 weeks since symptom onset Additionally, patients were stratified by age (60–74 years/75 + years) and presence of risk factors for severe RSV (excluding age), as selected based on the literature (see a full list of risk factors in legend of Table 1) [4, 26, 27]. To analyse risk factors, only comorbidities that were present at the time of RSV onset were included, where this information was known.Table 1Patient demographicsTotal(n = 1581, 100%)A-RSV(n = 237, 15.0%)O-RSV(n = 196, 12.4%)P-RSV(n = 588, 37.2%)H-RSV(n = 560, 35.4%)Country, n (%) France213 (13.5%)25 (10.5%)31 (15.8%)83 (14.1%)74 (13.2%) Germany438 (27.7%)92 (38.8%)45 (23%)142 (24.1%)159 (28.4%) Italy403 (25.5%)52 (21.9%)70 (35.7%)179 (30.4%)102 (18.2%) Spain371 (23.5%)54 (22.8%)36 (18.4%)134 (22.8%)147 (26.3%) UK156 (9.9%)14 (5.9%)14 (7.1%)50 (8.5%)78 (13.9%)Patients age, n (%) Mean (SD)71.34 (7.45)70.09 (6.69)70.53 (7.19)71.29 (7.32)72.21 (7.86) 60–741102 (69.7%)188 (79.3%)144 (73.5%)401 (68.2%)369 (65.9%) 75 +479 (30.3%)49 (20.7%)52 (26.5%)187 (31.8%)191 (34.1%)Patient gender, n (%) Female793 (50.2%)117 (49.4%)100 (51%)302 (51.4%)274 (48.9%) Male788 (49.8%)120 (50.6%)96 (49%)286 (48.6%)286 (51.1%)BMI, mean (SD)26.24 (4.00)25.82 (3.52)26.2 (3.54)26.12 (3.88)26.57 (4.42)Smoking status, n (%)Basen = 1547n = 229n = 196n = 587n = 559 Current smoker or ex-smoker926 (59.9%)104 (45.4%)114 (59.1%)332 (57.5%)376 (68.6%) Never smoked621 (40.1%)125 (54.6%)79 (40.9%)245 (42.5%)172 (31.4%)Employment, n (%) Not working due to retirement1108 (70.1%)167 (70.5%)129 (65.8%)397 (67.5%)415 (74.1%) Working full or part time234 (14.8%)36 (15.2%)36 (18.4%)89 (15.1%)73 (13%) Other1229 (14.5%)32 (13.5%)31 (15.8%)101 (17.2%)65 (11.6%)Ethnicity, n (%)Base2n = 1368n = 212n = 165n = 505n = 486 White1311 (95.8%)205 (96.7%)154 (93.3%)482 (95.4%)470 (96.7%) Other ethnicity360 (4.4%)7 (3.3%)11 (6.7%)25 (5%)17 (3.5%)Number of concomitant conditions diagnosed prior to most recent RSV episode4, n (%), baseBasen = 1581n = 237n = 196n = 588n = 5600 Concomitant conditions453 (28.7%)90 (38.0%)68 (34.7%)176 (29.9%)119 (21.3%)1 Concomitant condition520 (32.9%)100 (42.2%)55 (28.1%)177 (30.1%)188 (33.6%)2 Concomitant conditions338 (21.4%)25 (10.5%)43 (21.9%)142 (24.1%)128 (22.9%)3 + Concomitant conditions270 (17.1%)22 (9.3%)30 (15.3%)93 (15.8%)125 (22.3%)Conditions diagnosed prior to most recent RSV episode4, basen = 1581n = 237n = 196n = 588n = 560Cardiovascular651 (41.2%)87 (36.7%)75 (38.3%)250 (42.5%)239 (42.7%) Hypertension501 (31.7%)72 (30.4%)60 (30.6%)197 (33.5%)172 (30.7%) Congestive heart failure152 (9.6%)18 (7.6%)15 (7.7%)50 (8.5%)69 (12.3%) Coronary heart disease85 (5.4%)6 (2.5%)5 (2.6%)39 (6.6%)35 (6.3%)Respiratory565 (35.7%)52 (21.9%)49 (25.0%)194 (33.0%)270 (48.2%) COPD350 (22.1%)28 (11.8%)26 (13.3%)120 (20.4%)176 (31.4%) Asthma177 (11.2%)20 (8.4%)19 (9.7%)68 (11.6%)70 (12.5%)Psychological330 (20.9%)37 (15.6%)46 (23.5%)130 (22.1%)117 (20.9%) Depression202 (12.8%)23 (9.7%)26 (13.3%)72 (12.2%)81 (14.5%) Anxiety190 (12%)19 (8%)29 (14.8%)80 (13.6%)62 (11.1%)Metabolic143 (9%)10 (4.2%)22 (11.2%)43 (7.3%)68 (12.1%) Chronic kidney disease (CKD)89 (5.6%)3 (1.3%)14 (7.1%)30 (5.1%)42 (7.5%)Other64 (4%)4 (1.7%)11 (5.6%)23 (3.9%)26 (4.6%)Haematological17 (1.1%)1 (0.4%)2 (1%)8 (1.4%)6 (1.1%)Presence of risk factors for severe RSV, n (%)5 With risk factor/s1177 (74.4%)147 (62%)131 (66.8%)418 (71.1%)481 (85.9%) Without risk factor/s404 (25.6%)90 (38%)65 (33.2%)170 (28.9%)79 (14.1%)RF risk factors, SD standard deviation, RSV respiratory syncytial virus, A-RSV Acute respiratory syncytial virus, O-RSV ongoing respiratory syncytial virus, P-RSV post-acute respiratory syncytial virus, H-RSV post-hospital discharge respiratory syncytial virus1On long-term sick leave, homemaker, unemployed, unknown2Excluding France3Other ethnicity includes Black African or Caribbean, American Indian, Indigenous American, Alaska Native, or Other (specify)4Only conditions diagnosed prior to the most recent RSV episode and experienced by >5% of the population are listedCardiovascular: pulmonary embolism, pulmonary hypertension, coronary heart disease, cardiomyopathy, hypertension, congestive heart failureRespiratory: asthma, COPD, asthma and COPD (ACOS), interstitial lung disease (ILD), cystic fibrosis, pneumonia, bronchiolitis, bronchiectasisPsychological: depression, schizophrenia, anxietyMetabolic: chronic kidney disease (CKD), obesity; neurological: cerebrovascular disease, stroke; haematological: sickle cell anaemia, severe anaemia, thalassaemia, neutropeniaOther: immunosuppression, other5Risk factors for severe RSV: myocardial infarction, diabetes with/without chronic complications, renal disease, any malignancy including leukaemia and lymphoma, metastatic solid tumour, mild-severe liver disease, AIDS/HIV, long-term effects of COVID-19, dementia, chronic pulmonary disease, asthma, congestive heart failure, pneumonia, bronchiolitis, bronchiectasis, sickle cell anaemia, severe anaemia, thalassaemia, cerebrovascular disease, neutropenia, chronic kidney disease (CKD), stroke, immunosuppression, asthma and COPD (ACOS), interstitial lung disease (ILD), pulmonary embolism, pulmonary hypertension, cystic fibrosis, coronary heart disease, cardiomyopathy Table 1Patient demographicsTotal(n = 1581, 100%)A-RSV(n = 237, 15.0%)O-RSV(n = 196, 12.4%)P-RSV(n = 588, 37.2%)H-RSV(n = 560, 35.4%)Country, n (%) France213 (13.5%)25 (10.5%)31 (15.8%)83 (14.1%)74 (13.2%) Germany438 (27.7%)92 (38.8%)45 (23%)142 (24.1%)159 (28.4%) Italy403 (25.5%)52 (21.9%)70 (35.7%)179 (30.4%)102 (18.2%) Spain371 (23.5%)54 (22.8%)36 (18.4%)134 (22.8%)147 (26.3%) UK156 (9.9%)14 (5.9%)14 (7.1%)50 (8.5%)78 (13.9%)Patients age, n (%) Mean (SD)71.34 (7.45)70.09 (6.69)70.53 (7.19)71.29 (7.32)72.21 (7.86) 60–741102 (69.7%)188 (79.3%)144 (73.5%)401 (68.2%)369 (65.9%) 75 +479 (30.3%)49 (20.7%)52 (26.5%)187 (31.8%)191 (34.1%)Patient gender, n (%) Female793 (50.2%)117 (49.4%)100 (51%)302 (51.4%)274 (48.9%) Male788 (49.8%)120 (50.6%)96 (49%)286 (48.6%)286 (51.1%)BMI, mean (SD)26.24 (4.00)25.82 (3.52)26.2 (3.54)26.12 (3.88)26.57 (4.42)Smoking status, n (%)Basen = 1547n = 229n = 196n = 587n = 559 Current smoker or ex-smoker926 (59.9%)104 (45.4%)114 (59.1%)332 (57.5%)376 (68.6%) Never smoked621 (40.1%)125 (54.6%)79 (40.9%)245 (42.5%)172 (31.4%)Employment, n (%) Not working due to retirement1108 (70.1%)167 (70.5%)129 (65.8%)397 (67.5%)415 (74.1%) Working full or part time234 (14.8%)36 (15.2%)36 (18.4%)89 (15.1%)73 (13%) Other1229 (14.5%)32 (13.5%)31 (15.8%)101 (17.2%)65 (11.6%)Ethnicity, n (%)Base2n = 1368n = 212n = 165n = 505n = 486 White1311 (95.8%)205 (96.7%)154 (93.3%)482 (95.4%)470 (96.7%) Other ethnicity360 (4.4%)7 (3.3%)11 (6.7%)25 (5%)17 (3.5%)Number of concomitant conditions diagnosed prior to most recent RSV episode4, n (%), baseBasen = 1581n = 237n = 196n = 588n = 5600 Concomitant conditions453 (28.7%)90 (38.0%)68 (34.7%)176 (29.9%)119 (21.3%)1 Concomitant condition520 (32.9%)100 (42.2%)55 (28.1%)177 (30.1%)188 (33.6%)2 Concomitant conditions338 (21.4%)25 (10.5%)43 (21.9%)142 (24.1%)128 (22.9%)3 + Concomitant conditions270 (17.1%)22 (9.3%)30 (15.3%)93 (15.8%)125 (22.3%)Conditions diagnosed prior to most recent RSV episode4, basen = 1581n = 237n = 196n = 588n = 560Cardiovascular651 (41.2%)87 (36.7%)75 (38.3%)250 (42.5%)239 (42.7%) Hypertension501 (31.7%)72 (30.4%)60 (30.6%)197 (33.5%)172 (30.7%) Congestive heart failure152 (9.6%)18 (7.6%)15 (7.7%)50 (8.5%)69 (12.3%) Coronary heart disease85 (5.4%)6 (2.5%)5 (2.6%)39 (6.6%)35 (6.3%)Respiratory565 (35.7%)52 (21.9%)49 (25.0%)194 (33.0%)270 (48.2%) COPD350 (22.1%)28 (11.8%)26 (13.3%)120 (20.4%)176 (31.4%) Asthma177 (11.2%)20 (8.4%)19 (9.7%)68 (11.6%)70 (12.5%)Psychological330 (20.9%)37 (15.6%)46 (23.5%)130 (22.1%)117 (20.9%) Depression202 (12.8%)23 (9.7%)26 (13.3%)72 (12.2%)81 (14.5%) Anxiety190 (12%)19 (8%)29 (14.8%)80 (13.6%)62 (11.1%)Metabolic143 (9%)10 (4.2%)22 (11.2%)43 (7.3%)68 (12.1%) Chronic kidney disease (CKD)89 (5.6%)3 (1.3%)14 (7.1%)30 (5.1%)42 (7.5%)Other64 (4%)4 (1.7%)11 (5.6%)23 (3.9%)26 (4.6%)Haematological17 (1.1%)1 (0.4%)2 (1%)8 (1.4%)6 (1.1%)Presence of risk factors for severe RSV, n (%)5 With risk factor/s1177 (74.4%)147 (62%)131 (66.8%)418 (71.1%)481 (85.9%) Without risk factor/s404 (25.6%)90 (38%)65 (33.2%)170 (28.9%)79 (14.1%)RF risk factors, SD standard deviation, RSV respiratory syncytial virus, A-RSV Acute respiratory syncytial virus, O-RSV ongoing respiratory syncytial virus, P-RSV post-acute respiratory syncytial virus, H-RSV post-hospital discharge respiratory syncytial virus1On long-term sick leave, homemaker, unemployed, unknown2Excluding France3Other ethnicity includes Black African or Caribbean, American Indian, Indigenous American, Alaska Native, or Other (specify)4Only conditions diagnosed prior to the most recent RSV episode and experienced by >5% of the population are listedCardiovascular: pulmonary embolism, pulmonary hypertension, coronary heart disease, cardiomyopathy, hypertension, congestive heart failureRespiratory: asthma, COPD, asthma and COPD (ACOS), interstitial lung disease (ILD), cystic fibrosis, pneumonia, bronchiolitis, bronchiectasisPsychological: depression, schizophrenia, anxietyMetabolic: chronic kidney disease (CKD), obesity; neurological: cerebrovascular disease, stroke; haematological: sickle cell anaemia, severe anaemia, thalassaemia, neutropeniaOther: immunosuppression, other5Risk factors for severe RSV: myocardial infarction, diabetes with/without chronic complications, renal disease, any malignancy including leukaemia and lymphoma, metastatic solid tumour, mild-severe liver disease, AIDS/HIV, long-term effects of COVID-19, dementia, chronic pulmonary disease, asthma, congestive heart failure, pneumonia, bronchiolitis, bronchiectasis, sickle cell anaemia, severe anaemia, thalassaemia, cerebrovascular disease, neutropenia, chronic kidney disease (CKD), stroke, immunosuppression, asthma and COPD (ACOS), interstitial lung disease (ILD), pulmonary embolism, pulmonary hypertension, cystic fibrosis, coronary heart disease, cardiomyopathy Patient demographics RF risk factors, SD standard deviation, RSV respiratory syncytial virus, A-RSV Acute respiratory syncytial virus, O-RSV ongoing respiratory syncytial virus, P-RSV post-acute respiratory syncytial virus, H-RSV post-hospital discharge respiratory syncytial virus 1On long-term sick leave, homemaker, unemployed, unknown 2Excluding France 3Other ethnicity includes Black African or Caribbean, American Indian, Indigenous American, Alaska Native, or Other (specify) 4Only conditions diagnosed prior to the most recent RSV episode and experienced by >5% of the population are listed Cardiovascular: pulmonary embolism, pulmonary hypertension, coronary heart disease, cardiomyopathy, hypertension, congestive heart failure Respiratory: asthma, COPD, asthma and COPD (ACOS), interstitial lung disease (ILD), cystic fibrosis, pneumonia, bronchiolitis, bronchiectasis Psychological: depression, schizophrenia, anxiety Metabolic: chronic kidney disease (CKD), obesity; neurological: cerebrovascular disease, stroke; haematological: sickle cell anaemia, severe anaemia, thalassaemia, neutropenia Other: immunosuppression, other 5Risk factors for severe RSV: myocardial infarction, diabetes with/without chronic complications, renal disease, any malignancy including leukaemia and lymphoma, metastatic solid tumour, mild-severe liver disease, AIDS/HIV, long-term effects of COVID-19, dementia, chronic pulmonary disease, asthma, congestive heart failure, pneumonia, bronchiolitis, bronchiectasis, sickle cell anaemia, severe anaemia, thalassaemia, cerebrovascular disease, neutropenia, chronic kidney disease (CKD), stroke, immunosuppression, asthma and COPD (ACOS), interstitial lung disease (ILD), pulmonary embolism, pulmonary hypertension, cystic fibrosis, coronary heart disease, cardiomyopathy Where physician-reported patient symptoms were analysed, symptoms were grouped according to the domains outlined in [13], which were in turn drawn from the domains of the RiiQ™ . Additional symptoms associated with RSV that were included in the physician-reported forms, but not captured in the RiiQ™, were allocated to the aforementioned domains. Means and standard deviations (SD) or medians and interquartile ranges (IQR) were reported for continuous variables (where appropriate), with frequency counts and percentages reported for categorical variables. T-tests and analyses of variance (ANOVAs) were used to compare means for numeric variables, while Mann-Whitney U (MW) tests and Kruskal-Wallis (KW) tests were used to compare ordinal response options. Pairwise testing was not conducted. As the analysis was undertaken using secondary data derived without prior hypothesis, no formal sample size calculations were performed. The sample size was determined by the duration of the survey period and the willingness of the physicians and their patients to participate. Due to the nature of data collection and the availability of certain data points, missing data were possible. Missing data were not imputed; therefore, the number of patients included for each measure was reported. All analyses were conducted in Stata v19 [28]. Results Patient Demographics and Clinical Characteristics In total, 602 physicians completed patient record forms for 1581 of their consulting patients with RSV. Of these patients, 417 (26.4%) completed the voluntary patient-reported questionnaire reporting on their HRQoL. Overall, 65.1% of participating physicians consulted in a primary care setting, and 34.9% consulted in a secondary care setting. Regarding RSV severity status and symptom duration, n = 237 patients (15.0%) were classified as A-RSV, n = 196 (12.4%) as O-RSV, n = 588 (37.2%) as P-RSV and n = 560 (35.4%) as H-RSV. Full patient demographics and clinical characteristics are shown in Table 1. Patient demographics stratified by age and presence of risk factors are reported in Supplementary Table 1a and by country in Supplementary Table 1b. Of the 417 patients who provided patient perspective and PROM data, demographics and clinical characteristics are given in Supplementary Table 1c. When patients were stratified by age; 69.7% of patients were aged 60–74 and 30.3% were aged 75 +. For those with A-RSV, 20.7% were aged 75 +, whereas for those with H-RSV, this was 34.1%. Overall, 59.9% of patients were current or ex-smokers. For those with A-RSV, this was 45.4%, whereas for those with H-RSV, this was 68.6%. Regarding concomitant conditions diagnosed prior to the most recent RSV episode, the proportion of patients with 0, 1, 2 or 3 + concomitant conditions was 28.7%, 32.9%, 21.4% and 17.1%, respectively. In those with A-RSV, 9.3% had 3 + concomitant conditions, whereas for those with H-RSV, this was 22.3%. When stratified by severity and symptom duration, 36.7% of patients with A-RSV and 42.7% of patients with H-RSV had a cardiovascular condition, and 21.9% of patients with A-RSV and 48.2% of patients with H-RSV had a respiratory condition (Table 1). When concomitant conditions were further assessed, 74.4% of patients were defined as having a risk factor associated with severe RSV. In the A-RSV group this was 62.0%, and in the H-RSV group this was 85.9%. Patient Journey Among patients diagnosed with RSV, the times between symptom onset and diagnosis were similar between the RSV severity and symptom duration groups, as shown in Fig. 1. Overall, patients experienced a median (IQR) delay of 2.0 (0.0–4.0) days from symptom onset to first consultation and a median (IQR) delay of 0.0 (0.1–1.0) days from first consultation to diagnosis. Overall, the median (IQR) delay from symptom onset to diagnosis was 3.0 (1.0–6.0) days.Fig. 1Patient journey. SD = standard deviation, RSV = respiratory syncytial virus, A-RSV = acute respiratory syncytial virus, O-RSV = ongoing respiratory syncytial virus, P-RSV = post-acute respiratory syncytial virus, H-RSV = post-hospital discharge respiratory syncytial virus Patient journey. SD = standard deviation, RSV = respiratory syncytial virus, A-RSV = acute respiratory syncytial virus, O-RSV = ongoing respiratory syncytial virus, P-RSV = post-acute respiratory syncytial virus, H-RSV = post-hospital discharge respiratory syncytial virus The patient journey, stratified by age and presence of risk factors, is shown in Supplementary Figure 1. Patient Symptomatology Symptomology at Diagnosis At diagnosis, physicians reported that 95.7% of patients were experiencing systemic symptoms (tiredness/fatigue, fever, low energy etc.), 81.0% had upper respiratory symptoms (cough, sore throat, nasal congestion etc.), and 73.8% had lower respiratory symptoms (shortness of breath/difficulty breathing, uncomfortable breathing/chest tightness, wheezing, etc.). When stratified by severity and symptom duration, 60.3% of patients with A-RSV and 86.2% of patients with H-RSV were reported to have lower respiratory symptoms, respectively (Table 2). At the time of diagnosis, physicians reported that 30.0% of patients had mild RSV, 54.5% had moderate RSV, and 15.4% had severe or critical RSV. When stratified by severity and symptom duration, 45.1% of patients with A-RSV and 13.8% of patients with H-RSV had mild RSV at diagnosis, whereas 2.1% of patients with A-RSV and 31.4% of patients with H-RSV were reported to have severe or critical RSV.Table 2Physician-reported patient symptomatologyTotal (n = 1581)A-RSV (n = 237)O-RSV (n = 196)P-RSV (n = 588)H-RSV (n = 560)At diagnosisTop 3 symptoms experienced at diagnosis, basen = 1566n = 237n = 193n = 579n = 557Systemic symptoms1498 (95.7%)226 (95.4%)187 (96.9%)547 (94.5%)538 (96.6%) Tiredness/fatigue1108 (70.8%)167 (70.5%)133 (68.9%)396 (68.4%)412 (74%) Fever978 (62.5%)138 (58.2%)119 (61.7%)346 (59.8%)375 (67.3%) Low energy694 (44.3%)96 (40.5%)87 (45.1%)266 (45.9%)245 (44%)Upper respiratory symptoms1269 (81%)198 (83.5%)162 (83.9%)467 (80.7%)442 (79.4%) Cough1053 (67.2%)156 (65.8%)131 (67.9%)380 (65.6%)386 (69.3%) Sore throat526 (33.6%)95 (40.1%)57 (29.5%)205 (35.4%)169 (30.3%) Nasal congestion512 (32.7%)96 (40.5%)64 (33.2%)202 (34.9%)150 (26.9%)Lower respiratory symptoms1155 (73.8%)143 (60.3%)125 (64.8%)407 (70.3%)480 (86.2%) Shortness of breath/difficulty breathing996 (63.6%)112 (47.3%)105 (54.4%)351 (60.6%)428 (76.8%) Uncomfortable breathing/chest tightness612 (39.1%)67 (28.3%)58 (30.1%)212 (36.6%)275 (49.4%) Wheezing356 (22.7%)37 (15.6%)31 (16.1%)99 (17.1%)189 (33.9%)Severity of RSV at time of diagnosis, basen = 1581n = 237n = 196n = 588n = 560 Mild475 (30%)107 (45.1%)74 (37.8%)217 (36.9%)77 (13.8%) Moderate862 (54.5%)125 (52.7%)107 (54.6%)323 (54.9%)307 (54.8%) Severe or critical244 (15.4%)5 (2.1%)15 (7.7%)48 (8.2%)176 (31.4%)Number of times diagnosed with RSV, basen = 1203n = 176n = 155n = 444n = 428Mean (SD)1.06 (0.29)1.05 (0.27)1.06 (0.31)1.07 (0.31)1.06 (0.28)At time of data collectionTop 3 symptoms experienced at time of data collection, basen = 1581n = 237n = 196n = 588n = 560Systemic symptoms1261 (79.8%)197 (83.1%)145 (74%)469 (79.8%)450 (80.4%) Tiredness/fatigue935 (59.1%)133 (56.1%)103 (52.6%)349 (59.4%)350 (62.5%) Low energy529 (33.5%)69 (29.1%)60 (30.6%)211 (35.9%)189 (33.8%) Sleep disturbance244 (15.4%)25 (10.5%)26 (13.3%)121 (20.6%)72 (12.9%)Upper respiratory symptoms706 (44.7%)160 (67.5%)105 (53.6%)248 (42.2%)193 (34.5%) Cough552 (34.9%)123 (51.9%)82 (41.8%)187 (31.8%)160 (28.6%) Nasal congestion124 (7.8%)54 (22.8%)14 (7.1%)35 (6%)21 (3.8%) Rhinitis (runny nose)120 (7.6%)39 (16.5%)22 (11.2%)41 (7%)18 (3.2%)Lower respiratory symptoms637 (40.3%)97 (40.9%)49 (25%)244 (41.5%)247 (44.1%) Shortness of breath/difficulty breathing492 (31.1%)80 (33.8%)35 (17.9%)186 (31.6%)191 (34.1%) Uncomfortable breathing/chest tightness204 (12.9%)32 (13.5%)15 (7.7%)84 (14.3%)73 (13%) Wheezing169 (10.7%)21 (8.9%)12 (6.1%)56 (9.5%)80 (14.3%)Top 3 most troublesome symptoms at data collection1, basen = 1122n = 189n = 133n = 441n = 359Systemic symptoms500 (44.6%)70 (37%)72 (54.1%)217 (49.2%)141 (39.3%) Tiredness/fatigue254 (22.6%)35 (18.5%)34 (25.6%)110 (24.9%)75 (20.9%) Low energy64 (5.7%)7 (3.7%)8 (6%)23 (5.2%)26 (7.2%) Body aches51 (4.5%)13 (6.9%)7 (5.3%)19 (4.3%)12 (3.3%)Upper respiratory symptoms208 (18.5%)55 (29.1%)30 (22.6%)69 (15.6%)54 (15%) Cough161 (14.3%)45 (23.8%)21 (15.8%)52 (11.8%)43 (12%) Sore throat16 (1.4%)4 (2.1%)0 (0%)4 (0.9%)8 (2.2%) Rhinitis (runny nose)13 (1.2%)5 (2.6%)6 (4.5%)0 (0%)2 (0.6%)Lower respiratory symptoms409 (36.5%)63 (33.3%)29 (21.8%)153 (34.7%)164 (45.7%) Shortness of breath/difficulty breathing298 (26.6%)48 (25.4%)24 (18%)104 (23.6%)122 (34%) Uncomfortable breathing/chest tightness79 (7%)11 (5.8%)4 (3%)37 (8.4%)27 (7.5%) Wheezing27 (2.4%)4 (2.1%)1 (0.8%)10 (2.3%)12 (3.3%)Is this patient currently experiencing any of the following complications of RSV?n = 1581n = 237n = 196n = 588n = 560Any complication2740 (46.8%)72 (30.4%)77 (39.3%)319 (54.3%)154 (27.5%)Worsening of pre-existing comorbidities, e.g., asthma, COPD343 (21.7%)28 (11.8%)26 (13.3%)135 (23%)119 (21.3%)Lung infection230 (14.5%)16 (6.8%)24 (12.2%)71 (12.1%)97 (17.3%)Pneumonia147 (9.3%)7 (3%)7 (3.6%)36 (6.1%)59 (10.5%)1 Complication545 (34.5%)48 (20.3%)54 (27.6%)232 (39.5%)211 (37.7%)2 Complications203 (12.8%)13 (5.5%)19 (9.7%)63 (10.7%)108 (19.3%)3 + Complications93 (5.9%)11 (4.6%)4 (2%)24 (4.1%)54 (9.6%)None841 (53.2%)165 (69.6%)119 (60.7%)269 (45.7%)373 (66.6%)Number of concomitant conditions diagnosed after most recent RSV episode, n (%), base Basen = 1581n = 237n = 196n = 588n = 560 0 Concomitant conditions1343 (84.9%)225 (94.9%)177 (90.3%)482 (82.0%)459 (82.0%) 1 Concomitant condition163 (10.3%)9 (3.8%)12 (6.1%)72 (12.2%)70 (12.5%) 2 Concomitant conditions43 (2.7%)2 (0.8%)4 (2.0%)18 (3.1%)19 (3.4%) 3 + Concomitant conditions32 (2.0%)1 (0.4%)3 (1.5%)16 (2.7%)12 (2.1%)Conditions diagnosed after most recent RSV episode3, basen = 1581n = 237n = 196n = 588n = 560Respiratory130 (8.2%)7 (3%)11 (5.6%)55 (9.4%)57 (10.2%) Pneumonia60 (3.8%)4 (1.7%)5 (2.6%)17 (2.9%)34 (6.1%) Bronchiolitis29 (1.8%)3 (1.3%)2 (1%)14 (2.4%)10 (1.8%) Bronchiectasis27 (1.7%)2 (0.8%)2 (1%)15 (2.6%)8 (1.4%) Asthma17 (1.1%)0 (0%)1 (0.5%)10 (1.7%)6 (1.1%)Psychological82 (5.2%)2 (0.8%)11 (5.6%)47 (8.0%)22 (3.9%) Anxiety60 (3.8%)1 (0.4%)7 (3.6%)38 (6.5%)14 (2.5%) Depression34 (2.2%)1 (0.4%)5 (2.6%)18 (3.1%)10 (1.8%)Cardiovascular65 (4.1%)3 (1.3%)4 (2%)23 (3.9%)35 (6.3%) Congestive heart failure35 (2.2%)1 (0.4%)0 (0%)9 (1.5%)25 (4.5%)Haematological10 (0.6%)2 (0.8%)0 (0%)1 (0.2%)7 (1.3%)Metabolic6 (0.4%)0 (0%)1 (0.5%)3 (0.5%)2 (0.4%)Neurological4 (0.3%)0 (0%)0 (0%)1 (0.2%)3 (0.5%)Other3 (0.2%)0 (0%)0 (0%)1 (0.2%)2 (0.4%)RSV respiratory syncytial virus, A-RSV acute respiratory syncytial virus, O-RSV ongoing respiratory syncytial virus, P-RSV post-acute respiratory syncytial virus, H-RSV post-hospital discharge respiratory syncytial virus, COPD chronic pulmonary hypertension1Question was multiple choice2Any complication includes bronchiolitis, lung infection, worsening of pre-existing comorbidities, e.g., asthma, COPD, acute respiratory distress syndrome, pneumonia, acute otitis media (middle ear infection), conjunctivitis, arrhythmias, myocardial injury, myocardial ischaemia, heart failure, other3Only conditions diagnosed after the most recent RSV episode and experienced by > 1% of the population are listedCardiovascular: pulmonary embolism, pulmonary hypertension, coronary heart disease, cardiomyopathy, hypertension, congestive heart failureRespiratory: asthma, COPD, asthma and COPD (ACOS), interstitial lung disease (ILD), cystic fibrosis, pneumonia, bronchiolitis, bronchiectasisPsychological: depression, schizophrenia, anxietyMetabolic: chronic kidney disease (CKD), obesityNeurological: cerebrovascular disease, stroke; haematological: sickle cell anaemia, severe anaemia, thalassemia, neutropenia;Other: immunosuppression, other Table 2Physician-reported patient symptomatologyTotal (n = 1581)A-RSV (n = 237)O-RSV (n = 196)P-RSV (n = 588)H-RSV (n = 560)At diagnosisTop 3 symptoms experienced at diagnosis, basen = 1566n = 237n = 193n = 579n = 557Systemic symptoms1498 (95.7%)226 (95.4%)187 (96.9%)547 (94.5%)538 (96.6%) Tiredness/fatigue1108 (70.8%)167 (70.5%)133 (68.9%)396 (68.4%)412 (74%) Fever978 (62.5%)138 (58.2%)119 (61.7%)346 (59.8%)375 (67.3%) Low energy694 (44.3%)96 (40.5%)87 (45.1%)266 (45.9%)245 (44%)Upper respiratory symptoms1269 (81%)198 (83.5%)162 (83.9%)467 (80.7%)442 (79.4%) Cough1053 (67.2%)156 (65.8%)131 (67.9%)380 (65.6%)386 (69.3%) Sore throat526 (33.6%)95 (40.1%)57 (29.5%)205 (35.4%)169 (30.3%) Nasal congestion512 (32.7%)96 (40.5%)64 (33.2%)202 (34.9%)150 (26.9%)Lower respiratory symptoms1155 (73.8%)143 (60.3%)125 (64.8%)407 (70.3%)480 (86.2%) Shortness of breath/difficulty breathing996 (63.6%)112 (47.3%)105 (54.4%)351 (60.6%)428 (76.8%) Uncomfortable breathing/chest tightness612 (39.1%)67 (28.3%)58 (30.1%)212 (36.6%)275 (49.4%) Wheezing356 (22.7%)37 (15.6%)31 (16.1%)99 (17.1%)189 (33.9%)Severity of RSV at time of diagnosis, basen = 1581n = 237n = 196n = 588n = 560 Mild475 (30%)107 (45.1%)74 (37.8%)217 (36.9%)77 (13.8%) Moderate862 (54.5%)125 (52.7%)107 (54.6%)323 (54.9%)307 (54.8%) Severe or critical244 (15.4%)5 (2.1%)15 (7.7%)48 (8.2%)176 (31.4%)Number of times diagnosed with RSV, basen = 1203n = 176n = 155n = 444n = 428Mean (SD)1.06 (0.29)1.05 (0.27)1.06 (0.31)1.07 (0.31)1.06 (0.28)At time of data collectionTop 3 symptoms experienced at time of data collection, basen = 1581n = 237n = 196n = 588n = 560Systemic symptoms1261 (79.8%)197 (83.1%)145 (74%)469 (79.8%)450 (80.4%) Tiredness/fatigue935 (59.1%)133 (56.1%)103 (52.6%)349 (59.4%)350 (62.5%) Low energy529 (33.5%)69 (29.1%)60 (30.6%)211 (35.9%)189 (33.8%) Sleep disturbance244 (15.4%)25 (10.5%)26 (13.3%)121 (20.6%)72 (12.9%)Upper respiratory symptoms706 (44.7%)160 (67.5%)105 (53.6%)248 (42.2%)193 (34.5%) Cough552 (34.9%)123 (51.9%)82 (41.8%)187 (31.8%)160 (28.6%) Nasal congestion124 (7.8%)54 (22.8%)14 (7.1%)35 (6%)21 (3.8%) Rhinitis (runny nose)120 (7.6%)39 (16.5%)22 (11.2%)41 (7%)18 (3.2%)Lower respiratory symptoms637 (40.3%)97 (40.9%)49 (25%)244 (41.5%)247 (44.1%) Shortness of breath/difficulty breathing492 (31.1%)80 (33.8%)35 (17.9%)186 (31.6%)191 (34.1%) Uncomfortable breathing/chest tightness204 (12.9%)32 (13.5%)15 (7.7%)84 (14.3%)73 (13%) Wheezing169 (10.7%)21 (8.9%)12 (6.1%)56 (9.5%)80 (14.3%)Top 3 most troublesome symptoms at data collection1, basen = 1122n = 189n = 133n = 441n = 359Systemic symptoms500 (44.6%)70 (37%)72 (54.1%)217 (49.2%)141 (39.3%) Tiredness/fatigue254 (22.6%)35 (18.5%)34 (25.6%)110 (24.9%)75 (20.9%) Low energy64 (5.7%)7 (3.7%)8 (6%)23 (5.2%)26 (7.2%) Body aches51 (4.5%)13 (6.9%)7 (5.3%)19 (4.3%)12 (3.3%)Upper respiratory symptoms208 (18.5%)55 (29.1%)30 (22.6%)69 (15.6%)54 (15%) Cough161 (14.3%)45 (23.8%)21 (15.8%)52 (11.8%)43 (12%) Sore throat16 (1.4%)4 (2.1%)0 (0%)4 (0.9%)8 (2.2%) Rhinitis (runny nose)13 (1.2%)5 (2.6%)6 (4.5%)0 (0%)2 (0.6%)Lower respiratory symptoms409 (36.5%)63 (33.3%)29 (21.8%)153 (34.7%)164 (45.7%) Shortness of breath/difficulty breathing298 (26.6%)48 (25.4%)24 (18%)104 (23.6%)122 (34%) Uncomfortable breathing/chest tightness79 (7%)11 (5.8%)4 (3%)37 (8.4%)27 (7.5%) Wheezing27 (2.4%)4 (2.1%)1 (0.8%)10 (2.3%)12 (3.3%)Is this patient currently experiencing any of the following complications of RSV?n = 1581n = 237n = 196n = 588n = 560Any complication2740 (46.8%)72 (30.4%)77 (39.3%)319 (54.3%)154 (27.5%)Worsening of pre-existing comorbidities, e.g., asthma, COPD343 (21.7%)28 (11.8%)26 (13.3%)135 (23%)119 (21.3%)Lung infection230 (14.5%)16 (6.8%)24 (12.2%)71 (12.1%)97 (17.3%)Pneumonia147 (9.3%)7 (3%)7 (3.6%)36 (6.1%)59 (10.5%)1 Complication545 (34.5%)48 (20.3%)54 (27.6%)232 (39.5%)211 (37.7%)2 Complications203 (12.8%)13 (5.5%)19 (9.7%)63 (10.7%)108 (19.3%)3 + Complications93 (5.9%)11 (4.6%)4 (2%)24 (4.1%)54 (9.6%)None841 (53.2%)165 (69.6%)119 (60.7%)269 (45.7%)373 (66.6%)Number of concomitant conditions diagnosed after most recent RSV episode, n (%), base Basen = 1581n = 237n = 196n = 588n = 560 0 Concomitant conditions1343 (84.9%)225 (94.9%)177 (90.3%)482 (82.0%)459 (82.0%) 1 Concomitant condition163 (10.3%)9 (3.8%)12 (6.1%)72 (12.2%)70 (12.5%) 2 Concomitant conditions43 (2.7%)2 (0.8%)4 (2.0%)18 (3.1%)19 (3.4%) 3 + Concomitant conditions32 (2.0%)1 (0.4%)3 (1.5%)16 (2.7%)12 (2.1%)Conditions diagnosed after most recent RSV episode3, basen = 1581n = 237n = 196n = 588n = 560Respiratory130 (8.2%)7 (3%)11 (5.6%)55 (9.4%)57 (10.2%) Pneumonia60 (3.8%)4 (1.7%)5 (2.6%)17 (2.9%)34 (6.1%) Bronchiolitis29 (1.8%)3 (1.3%)2 (1%)14 (2.4%)10 (1.8%) Bronchiectasis27 (1.7%)2 (0.8%)2 (1%)15 (2.6%)8 (1.4%) Asthma17 (1.1%)0 (0%)1 (0.5%)10 (1.7%)6 (1.1%)Psychological82 (5.2%)2 (0.8%)11 (5.6%)47 (8.0%)22 (3.9%) Anxiety60 (3.8%)1 (0.4%)7 (3.6%)38 (6.5%)14 (2.5%) Depression34 (2.2%)1 (0.4%)5 (2.6%)18 (3.1%)10 (1.8%)Cardiovascular65 (4.1%)3 (1.3%)4 (2%)23 (3.9%)35 (6.3%) Congestive heart failure35 (2.2%)1 (0.4%)0 (0%)9 (1.5%)25 (4.5%)Haematological10 (0.6%)2 (0.8%)0 (0%)1 (0.2%)7 (1.3%)Metabolic6 (0.4%)0 (0%)1 (0.5%)3 (0.5%)2 (0.4%)Neurological4 (0.3%)0 (0%)0 (0%)1 (0.2%)3 (0.5%)Other3 (0.2%)0 (0%)0 (0%)1 (0.2%)2 (0.4%)RSV respiratory syncytial virus, A-RSV acute respiratory syncytial virus, O-RSV ongoing respiratory syncytial virus, P-RSV post-acute respiratory syncytial virus, H-RSV post-hospital discharge respiratory syncytial virus, COPD chronic pulmonary hypertension1Question was multiple choice2Any complication includes bronchiolitis, lung infection, worsening of pre-existing comorbidities, e.g., asthma, COPD, acute respiratory distress syndrome, pneumonia, acute otitis media (middle ear infection), conjunctivitis, arrhythmias, myocardial injury, myocardial ischaemia, heart failure, other3Only conditions diagnosed after the most recent RSV episode and experienced by > 1% of the population are listedCardiovascular: pulmonary embolism, pulmonary hypertension, coronary heart disease, cardiomyopathy, hypertension, congestive heart failureRespiratory: asthma, COPD, asthma and COPD (ACOS), interstitial lung disease (ILD), cystic fibrosis, pneumonia, bronchiolitis, bronchiectasisPsychological: depression, schizophrenia, anxietyMetabolic: chronic kidney disease (CKD), obesityNeurological: cerebrovascular disease, stroke; haematological: sickle cell anaemia, severe anaemia, thalassemia, neutropenia;Other: immunosuppression, other Physician-reported patient symptomatology RSV respiratory syncytial virus, A-RSV acute respiratory syncytial virus, O-RSV ongoing respiratory syncytial virus, P-RSV post-acute respiratory syncytial virus, H-RSV post-hospital discharge respiratory syncytial virus, COPD chronic pulmonary hypertension 1Question was multiple choice 2Any complication includes bronchiolitis, lung infection, worsening of pre-existing comorbidities, e.g., asthma, COPD, acute respiratory distress syndrome, pneumonia, acute otitis media (middle ear infection), conjunctivitis, arrhythmias, myocardial injury, myocardial ischaemia, heart failure, other 3Only conditions diagnosed after the most recent RSV episode and experienced by > 1% of the population are listed Cardiovascular: pulmonary embolism, pulmonary hypertension, coronary heart disease, cardiomyopathy, hypertension, congestive heart failure Respiratory: asthma, COPD, asthma and COPD (ACOS), interstitial lung disease (ILD), cystic fibrosis, pneumonia, bronchiolitis, bronchiectasis Psychological: depression, schizophrenia, anxiety Metabolic: chronic kidney disease (CKD), obesity Neurological: cerebrovascular disease, stroke; haematological: sickle cell anaemia, severe anaemia, thalassemia, neutropenia; Other: immunosuppression, other Symptoms at Data Collection At the point of data collection, physicians reported that 79.8% of patients were experiencing systemic symptoms, 44.7% were experiencing upper respiratory symptoms, and 40.3% were experiencing lower respiratory symptoms. When stratified by severity and symptom duration, 67.5% of patients with A-RSV and 34.5% of patients with H-RSV were reported to have upper respiratory symptoms, respectively (Table 2). Regarding physicians' perspectives of the most bothersome RSV-related symptoms, at the time of data collection, physicians reported that systemic symptoms (44.6%), lower respiratory symptoms (36.5%) and upper respiratory symptoms (18.5%) were the most bothersome to their patients. When stratified by severity and symptom duration, upper respiratory symptoms were reported to be most bothersome for 29.1% of patients with A-RSV and 15.0% of patients with H-RSV, respectively. Lower respiratory symptoms were reported to be most bothersome for 33.3% of patients with A-RSV and 45.7% of patients with H-RSV, respectively. Overall, 46.8% of patients were reported to be experiencing a complication of RSV at the time of data collection. The number of patients with one complication, two complications or 3 + complications was 34.5%, 12.8% and 5.9%, respectively (Table 2). Regarding the presence of concomitant conditions diagnosed after the most recent RSV episode, 8.2% of patients were subsequently diagnosed with a respiratory condition, 5.2% with a psychological condition and 4.1% with a cardiovascular condition following RSV infection. Patient symptomology, stratified by age and presence of risk factors, is given in Supplementary Table 2a, and stratified by country in Supplementary Table 2b. Physician-Reported Impact of RSV on HRQoL and Activities of Daily Living Physicians reported their perspectives on the impact of RSV across eight domains related to patient HRQoL and activities of daily living. At the point of data collection, significant differences between the severity and symptom duration groups were seen across all impact domains (all p < 0.01) (Fig. 2). Physicians perceived that RSV had a high impact on the overall quality of life in 19.7% of their patients, with 29.7% with H-RSV reported to be experiencing a high impact (p < 0.0001). Over half of RSV patients were reported to be experiencing severe physical fatigue, with 91% of H-RSV patients still experiencing moderate/severe physical fatigue a median of 7 weeks after diagnosis. A third of patients were experiencing severe mental fatigue, regardless of severity and symptom duration. Overall, > 50% patients in all groups were affected by moderate/severe pain, with 56.6% of patients with P-RSV experiencing moderate/severe pain on average 18 weeks after diagnosis and 24.3% of patients with H-RSV still experiencing severe pain an average 7 weeks after diagnosis.Fig. 2Physician-reported impact of RSV on patient HRQoL and activities of daily living. HRQoL = health-related quality of life, RSV = acute respiratory syncytial virus, A-RSV = acute respiratory syncytial virus, O-RSV = ongoing respiratory syncytial virus, P-RSV = post-acute respiratory syncytial virus, H-RSV = post-hospital discharge respiratory syncytial virus Physician-reported impact of RSV on patient HRQoL and activities of daily living. HRQoL = health-related quality of life, RSV = acute respiratory syncytial virus, A-RSV = acute respiratory syncytial virus, O-RSV = ongoing respiratory syncytial virus, P-RSV = post-acute respiratory syncytial virus, H-RSV = post-hospital discharge respiratory syncytial virus Physician-reported impacts of RSV, stratified by age and presence of risk factors, are shown in Supplementary Figure 2. Patients with pre-existing risk factors experienced greater impact than those who did not across all eight impact domains (all p < 0.001). Patients aged 75 + experienced greater impact than patients aged 60–74 across all impact domains except for severity of pain (all p < 0.001). Patient-Reported Health-Related Quality of Life A subset of patients (n = 417, 26.4%) voluntarily reported on their HRQoL using a range of validated PROM tools. As measured by RiiQ™ scores, a significantly higher burden across all symptom impact domains was reported by H-RSV patients than by patients without a history of RSV hospitalization (all p < 0.05). Additionally, the quality of life of H-RSV patients was significantly lower than that seen in the other groups (p = 0.0095) as measured by the EQ-5D-5L (Table 3).Table 3Patient-reported health-related quality of lifeTotal (n = 417)A-RSV (n = 111)O-RSV (n = 45)P-RSV (n = 130)H-RSV (n = 131)P valueRiiQ™RiiQ™ impact on daily activities domainn = 397n = 106n = 42n = 124n = 125Mean (SD)0.65 (0.71)0.65 (0.74)0.47 (0.54)0.50 (0.62)0.87 (0.76)0.0001 (AN)RiiQ™ impact on emotions domainn = 397n = 106n = 42n = 123n = 126Mean (SD)0.69 (0.67)0.60 (0.67)0.62 (0.59)0.59 (0.65)0.89 (0.68)0.0008 (AN)RiiQ™ impact on others domainn = 394n = 104n = 42n = 125n = 123Mean (SD)0.61 (0.62)0.61 (0.66)0.55 (0.53)0.48 (0.52)0.77 (0.67)0.003 (AN)RiiQ™ respiratory domainn = 366n = 98n = 38n = 112n = 118Mean (SD)0.70 (0.58)0.81 (0.56)0.63 (0.49)0.49 (0.55)0.84 (0.6)< 0.0001 (AN)RiiQ™ systemic symptoms domainn = 366n = 98n = 39n = 110n = 119Mean (SD)0.72 (0.57)0.72 (0.55)0.70 (0.58)0.60 (0.52)0.83 (0.61)0.0279 (AN)EQ5DEQ5D 5L–French tariffn = 406n = 108n = 43n = 126n = 129Mean (SD)0.87 (0.14)0.89 (0.11)0.90 (0.10)0.89 (0.11)0.83 (0.20)0.0021 (AN)EQ5D 5L-German tariffn = 406n = 108n = 43n = 126n = 129Mean (SD)0.82 (0.17)0.84 (0.14)0.86 (0.11)0.84 (0.13)0.78 (0.22)0.0043 (AN)EQ5D 5L-Italian tariffn = 406n = 108n = 43n = 126n = 129Mean (SD)0.80 (0.20)0.82 (0.16)0.84 (0.14)0.82 (0.16)0.75 (0.26)0.0038 (AN)EQ5D 5L-Spanish tariffn = 406n = 108n = 43n = 126n = 129Mean (SD)0.77 (0.17)0.80 (0.15)0.80 (0.15)0.78 (0.15)0.72 (0.21)0.0026 (AN)EQ5D 5L-UK tariffn = 406n = 108n = 43n = 126n = 129Mean (SD)0.70 (0.20)0.72 (0.17)0.74 (0.16)0.72 (0.18)0.65 (0.23)0.0086 (AN)EQ5D VAS scoren = 411n = 110n = 44n = 127n = 130Mean (SD)66.3 (17.46)67.68 (15.47)67.73 (17.83)66.56 (18.56)64.41 (17.85)0.47 (AN)AN ANOVA, RiiQ™ Respiratory Infection Intensity and Impact Questionnaire, EQ-5D-5L EuroQol five-dimensional five-level questionnaire, EQ-VAS EuroQol visual analogue scale, SD standard deviation, RSV respiratory syncytial virus, A-RSV acute respiratory syncytial virus, O-RSV ongoing respiratory syncytial virus, P-RSV post-acute respiratory syncytial virus, H-RSV post-hospital discharge respiratory syncytial virus Table 3Patient-reported health-related quality of lifeTotal (n = 417)A-RSV (n = 111)O-RSV (n = 45)P-RSV (n = 130)H-RSV (n = 131)P valueRiiQ™RiiQ™ impact on daily activities domainn = 397n = 106n = 42n = 124n = 125Mean (SD)0.65 (0.71)0.65 (0.74)0.47 (0.54)0.50 (0.62)0.87 (0.76)0.0001 (AN)RiiQ™ impact on emotions domainn = 397n = 106n = 42n = 123n = 126Mean (SD)0.69 (0.67)0.60 (0.67)0.62 (0.59)0.59 (0.65)0.89 (0.68)0.0008 (AN)RiiQ™ impact on others domainn = 394n = 104n = 42n = 125n = 123Mean (SD)0.61 (0.62)0.61 (0.66)0.55 (0.53)0.48 (0.52)0.77 (0.67)0.003 (AN)RiiQ™ respiratory domainn = 366n = 98n = 38n = 112n = 118Mean (SD)0.70 (0.58)0.81 (0.56)0.63 (0.49)0.49 (0.55)0.84 (0.6)< 0.0001 (AN)RiiQ™ systemic symptoms domainn = 366n = 98n = 39n = 110n = 119Mean (SD)0.72 (0.57)0.72 (0.55)0.70 (0.58)0.60 (0.52)0.83 (0.61)0.0279 (AN)EQ5DEQ5D 5L–French tariffn = 406n = 108n = 43n = 126n = 129Mean (SD)0.87 (0.14)0.89 (0.11)0.90 (0.10)0.89 (0.11)0.83 (0.20)0.0021 (AN)EQ5D 5L-German tariffn = 406n = 108n = 43n = 126n = 129Mean (SD)0.82 (0.17)0.84 (0.14)0.86 (0.11)0.84 (0.13)0.78 (0.22)0.0043 (AN)EQ5D 5L-Italian tariffn = 406n = 108n = 43n = 126n = 129Mean (SD)0.80 (0.20)0.82 (0.16)0.84 (0.14)0.82 (0.16)0.75 (0.26)0.0038 (AN)EQ5D 5L-Spanish tariffn = 406n = 108n = 43n = 126n = 129Mean (SD)0.77 (0.17)0.80 (0.15)0.80 (0.15)0.78 (0.15)0.72 (0.21)0.0026 (AN)EQ5D 5L-UK tariffn = 406n = 108n = 43n = 126n = 129Mean (SD)0.70 (0.20)0.72 (0.17)0.74 (0.16)0.72 (0.18)0.65 (0.23)0.0086 (AN)EQ5D VAS scoren = 411n = 110n = 44n = 127n = 130Mean (SD)66.3 (17.46)67.68 (15.47)67.73 (17.83)66.56 (18.56)64.41 (17.85)0.47 (AN)AN ANOVA, RiiQ™ Respiratory Infection Intensity and Impact Questionnaire, EQ-5D-5L EuroQol five-dimensional five-level questionnaire, EQ-VAS EuroQol visual analogue scale, SD standard deviation, RSV respiratory syncytial virus, A-RSV acute respiratory syncytial virus, O-RSV ongoing respiratory syncytial virus, P-RSV post-acute respiratory syncytial virus, H-RSV post-hospital discharge respiratory syncytial virus Patient-reported health-related quality of life AN ANOVA, RiiQ™ Respiratory Infection Intensity and Impact Questionnaire, EQ-5D-5L EuroQol five-dimensional five-level questionnaire, EQ-VAS EuroQol visual analogue scale, SD standard deviation, RSV respiratory syncytial virus, A-RSV acute respiratory syncytial virus, O-RSV ongoing respiratory syncytial virus, P-RSV post-acute respiratory syncytial virus, H-RSV post-hospital discharge respiratory syncytial virus Significant differences between severity and symptom duration groups were seen in the EQ-5D mobility, self-care and anxiety/depression domains (all p < 0.05). The highest impact of RSV was seen in the EQ-5D-5L pain/discomfort subdomain, where over a third of all patients had moderate-to-severe pain or discomfort, with almost half of H-RSV patients having pain or discomfort (at point of consultation, on average 7 weeks since diagnosis). RSV also impacted patients’ ability to do their usual activities, with > 70% of patients reporting that RSV has impacted their ability to do their usual activities, although differences in these domains were not statistically significant. Most patients with ongoing or post-acute RSV reported pain/discomfort (> 75% O-RSV and > 80% P-RSV) at the point of consultation, on average 6 and 18 weeks after diagnosis (Fig. 3).Fig. 3EQ-5D-5L domains. EQ-5D-5L = EuroQol-5 Dimension-5 Level, A-RSV = acute respiratory syncytial virus, O-RSV = ongoing respiratory syncytial virus, P-RSV = post-acute respiratory syncytial virus, H-RSV = post-hospital discharge respiratory syncytial virus EQ-5D-5L domains. EQ-5D-5L = EuroQol-5 Dimension-5 Level, A-RSV = acute respiratory syncytial virus, O-RSV = ongoing respiratory syncytial virus, P-RSV = post-acute respiratory syncytial virus, H-RSV = post-hospital discharge respiratory syncytial virus Patient-reported HRQoL data, including individual EQ-5D-5L tariffs for each country, stratified by age and presence of risk factors, and by country, are given in Supplementary Table 3a and 3b and Supplementary Figure 2 and 3. Discussion This study characterized the clinical and humanistic burden in older adults with RSV in Europe. The burden of RSV in older adults is increasingly being recognised [29, 30], particularly regarding the epidemiological burden [7] and the economic impact [4, 15, 31–34]. The results of our study further highlight the burden of RSV in people aged 60 + and the fact that symptoms can persist over a long period of time. Many patients in our sample were experiencing either O-RSV (12.4%) or P-RSV (37.2%), with symptoms persisting a median 6 weeks and 18 weeks after diagnosis, respectively. Furthermore, 35.4% of patients in our sample were recovering from RSV hospitalisation and were still experiencing symptoms of RSV at a median of 7 weeks after diagnosis. While patients in the O-RSV and P-RSV groups may have experienced different symptom burdens in the time between diagnosis and inclusion in this analysis, and patients in the A-RSV cohort may subsequently develop persistent or long-term symptoms over time. By stratifying patients in this manner, we were able to investigate the humanistic burden of patients in each cohort independently of the others. While patients in the H-RSV group could have experienced symptoms over any period of time, these were included as a separate group to help understand the additional burden experienced by patients who had been hospitalized. Risk factors associated with severe RSV, including older age and presence of comorbidities are well documented [3, 4, 10, 26, 27, 35–39]. This was also observed in our study sample; of patients with H-RSV, 34.1% were aged 75 + (vs A-RSV; 20.7%), 90.9% had 1 + concomitant conditions (vs A-RSV; 74.6%), 85.9% had pre-existing risk factor for severe RSV (vs A-RSV; 62.0%) and 68.6% were current or ex-smokers (vs A-RSV; 45.4%). Severity of RSV at diagnosis was also a factor in subsequent hospitalisations; 31.4% of patients with H-RSV were reported to have severe or critical RSV at diagnosis (vs A-RSV: 2.1%), with just 13.8% having mild RSV at diagnosis (vs A-RSV: 45.1%). Furthermore, a number of patients, and in particular those with H-RSV, were diagnosed with concomitant conditions (respiratory, psychological, cardiovascular) and other complications after their most recent RSV episode. This aligns with previous studies that have shown that RSV-related complications are common after RSV infection, specifically in patients with pre-existing risk factors [40]. Another study found an increased risk of cardiovascular events in adult patients 1 year post-RSV infection [41]. These findings highlight the importance of early diagnosis and close monitoring to minimize the development of more severe disease and potential complications. While the link between age and comorbidities on severity of RSV presentation and hospitalisations in older patients is well recognised, an understanding of the humanistic burden of RSV in terms of impact on HRQoL and activities of daily living is limited. In our study, physicians reported that RSV impacted patients across a range of domains, including psychological wellbeing, relationships, ability to support or care for family members, as well as physical and mental fatigue, and pain, with significant differences seen between severity and symptom duration groups. While HRQoL was impacted most in patients with H-RSV, RSV also had a long-term effect among patients with O-RSV and P-RSV, with symptomatic burden persisting over several months. Patients also reported the impact of RSV on their own HRQoL, with significant differences between severity and symptom duration groups seen across RiiQ™ symptom scores (all p < 0.05) and EQ-5D-5L scores (p < 0.05). Significant differences between groups were also seen in the EQ-5D mobility, self-care and anxiety/depression domains (all p < 0.05), with EQ-5D-5L and EQ-VAS scores in our sample lower than those compared with age-controlled general population groups in Europe [42, 43]. These results further highlight that RSV infection can have a prolonged impact on patients’ HRQoL, given that patients with O-RSV, P-RSV and H-RSV reported a greater impact on their HRQoL than patients with A-RSV. Differences in EQ-5D VAS scores between severity and symptom duration groups were not statistically significant, likely because at data collection, most patients were experiencing systemic symptoms of RSV (tiredness/fatigue, fever, low energy etc.) that would have impacted their overall HRQoL. Differences in RiiQ™ symptom scores may be explained by the fact that patients with A-RSV will be experiencing respiratory symptoms in relation to RSV at the time of data collection, whereas those with O-RSV and P-RSV are well beyond the acute respiratory symptoms phase and thus these symptoms will have resolved. Our data align with the results of a previous study that showed the impact of RSV on activities of daily living, social activities and relationships [12]. A further study highlighted the impact of RSV on fatigue, social functioning and emotional burden compared with those with an RSV negative acute respiratory infection [14]. Several studies have also compared the substantial severity and burden of RSV with other respiratory conditions. While some studies conclude the impact of RSV to be comparable to influenza [11, 27, 44–48], others state that RSV may lead to greater morbidity and mortality in older hospitalised adults than influenza [49, 50]. Studies have recommended vaccinations for RSV as a way of limiting humanistic burden in older patients or those at high risk, as well as reducing healthcare resource-related costs [33, 38, 39, 51–55], and a focus on preventative measures may help relieve this burden. Strengths and Limitations Our study has several strengths and limitations. Physicians provided data for a consecutive series of patients with clinically diagnosed RSV, with minimal inclusion criteria applied, to avoid selection bias and establish a representative sample of patients. Data were collected at the time of each patient’s appointment, and physicians had access to patient medical records for data extraction to mitigate recall bias. However, participation was dependent on willingness to complete the survey, and patient completion of questionnaires was voluntary. Furthermore, patients with RSV who visit their physician may be more severely affected, which may overstate the proportion of patients with more severe symptomatic presentation than those who did not seek medical attention. In our study, patients were required to have a physician-confirmed diagnosis of RSV via laboratory-based molecular testing to be eligible for inclusion. While a prospective study, with patients followed up longitudinally over a set period of time, may have enabled incidence estimation, besides systematic collection of symptomatic and HRQoL data, this objective was outside the scope of our study. Nonetheless, our cross-sectional study sample comprises a large multi-national sample of patients with humanistic burden from the patient perspective as well as reported by the physician, representative of a real-world consulting population. Conclusion RSV was associated with high clinical burden, with many patients experiencing high symptom burden, complications and worsening of comorbidities after RSV infection. Burden was particularly high depending on the severity and symptom duration, and patients reported low HRQoL across all outcome-reported measures. Importantly, in patients with O-RSV, P-RSV and H-RSV, symptomatic burden can persist for several weeks and months after the initial RSV infection. Given the high burden of RSV observed, a focus on preventive measures such as RSV vaccination should be prioritized. Supplementary Information Below is the link to the electronic supplementary material.Supplementary file1 (PDF 1414 kb) Supplementary file1 (PDF 1414 kb)